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The standard treatment for T4 locally advanced gastric cancer is gastrectomy with D2 lymph
node dissection followed by adjuvant chemotherapy with S-1 for 12 months; however, prog-
nostic outcome in Stage IIIb has been insufﬁcient. It is expected that survival is improved by
preoperative treatment with a triplet regimen of docetaxel, cisplatin and S-1 (divided DCS
therapy). A multicenter Phase II study has been conducted to evaluate the safety and efﬁcacy
of two courses of preoperative chemotherapy followed by gastrectomy. Fifty-ﬁve patients are
required for this study. The primary endpoint of the study is pathological response rate of
primary lesions. Secondary endpoints are overall survival, disease-free survival, R0 resection
rate and adverse events.
INTRODUCTION
The standard approach for locally advanced gastric cancer is
to achieve R0 resection. Although gastrectomy with D2
lymph node dissection, the so-called extended dissection in
western countries, has been undergone, peritoneal metastases
(relapse) has been found frequently in T4 gastric cancer. In
order to decrease incidence of relapse after R0 resection, post-
operative adjuvant chemotherapy is recommended. Recent
study, Adjuvant Chemotherapy Trial of S-1 for Gastric
Cancer (ACTS-GC), demonstrated that S-1 is an effective ad-
juvant treatment for East Asian patients who have undergone
D2 dissection for locally advance gastric cancer (1).
According to the subgroup analysis of ACTS-GC, there is no
prognostic difference between the patients with and without
S-1 in Stage IIIb. More intensive regimen, such as S-1 plus
cisplatin which has demonstrated a signiﬁcant higher response
rate and longer survival than S-1 alone in SPIRITS trials (2),
is needed for Stage IIIb consisting mostly of T4 gastric
cancer, while S-1 plus cisplatin should reveal low compliance
and high adverse events after gastrectomy (3, 4).
On the other hand, the potential beneﬁts of preoperative
chemotherapy include increasing the likelihood of curative
resection by down-staging of the tumor, eliminating micro-
metastases and improving compliance against chemotherapy
by avoiding surgery-related gastrointestinal symptoms.
Although MAGIC trial demonstrated that preoperative
chemotherapy achieved down-staging and revealed longer
survival than surgery alone, 5 years survival rate of surgery
alone in Japanese intergroup studies is 70% which is su-
perior to the result of preoperative chemotherapy in MAGIC
trial (5). It is reason why that Japanese standard surgery for
locally advanced gastric cancer is gastrectomy with D2
lymph node dissection, while D1 dissection is standard in
Western Europe.
S-1/CDDP regimen (where CDDP is cisplatin) has now
become one of the Japanese standards for unresectable or re-
current gastric cancer, because S-1 plus cisplatin has demon-
strated signiﬁcant higher response rate and longer survival
than S-1 alone in the SPIRITS trial. In a preoperative
setting, phase II study of S-1 plus cisplatin for the patients
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48% of pathological response rate (pRR) in the primary
lesion (6). Some reports described that a pRR to preoperative
chemotherapy may be a surrogate for longer survival (7), but
the efﬁcacy of S-1 plus cisplatin is not sufﬁcient in the view
point of the pRR. Therefore, the combination chemotherapy
consisting of docetaxel, cisplatin and S-1 (DCS therapy) has
been anticipated as a more powerful regimen of preoperative
setting for locally advanced gastric cancer.
We have already described the feasibility and efﬁcacy of
preoperative chemotherapy using DCS therapy in gastric
cancer patients with para-aortic lymph node metastases (8).
Fifteen patients received intravenous docetaxel and cisplatin
(30, 35 or 40 mg/m
2, each dose escalation was reciprocal) on
Day 1, and 15 and S-1 (40 mg/m
2 twice daily) on Day 1–14
every 4 weeks. Dose-limiting toxicities were neutropenia,
febrile neutropenia and diarrhea. Recommended dose of this
combination was presumed to be 35 mg/m
2 of docetaxel and
35 mg/m
2 of cisplatin. pRRs were 85% in primary lesions
and 92% in lymph node metastases after two cycles of
chemotherapy. These results were considered expectable for
locally advanced gastric cancer.
In the present study, we hypothesize that preoperative
chemotherapy combining DCS in T4 locally advanced
gastric cancer would induce a 70% of pRR. The aim of this
Phase II study was to evaluate the feasibility and efﬁcacy of
this regimen and to select a candidate for an experimental
arm in the next Phase III trial.
PROTOCOL DESIGN OF THE STUDY
PURPOSE
The aim of this study was to evaluate the safety and efﬁcacy
of preoperative chemotherapy with DCS for the treatment of
patients with locally advanced gastric cancer.
STUDY SETTING
The study is a multi-institutional prospective Phase II trial,
in which participating institutions included 25 specialized
centers as of 2011.
ENDPOINT
The primary endpoint is pRR of the primary lesion.
Secondary endpoints are overall survival, disease-free sur-
vival, R0 resection rate and adverse events deﬁned by
Common Terminology Criteria for Adverse Events version
3.0.
ELIGIBILITY CRITERIA
The primary tumor is staged according to the third English
edition of the Japanese Classiﬁcation of Gastric Carcinoma (9).
INCLUSION CRITERIA
Prior to enrollment in this study, patients must fulﬁll all of
the following criteria: histologically conﬁrmed gastric adeno-
carcinoma; T4 carcinoma that is staged according to the third
English edition of the Japanese Classiﬁcation of Gastric
Carcinoma, without distant metastases evident on chest, ab-
dominal and pelvic computed tomography (CT) and staging
laparoscopy; the length of esophageal invasion 3c m ;a g e
20–75 years; Eastern Cooperative Oncology Group perform-
ance status of 0–1; no prior chemotherapy or radiotherapy;
no major surgical procedure; no apparent bleeding from
primary lesion; fair oral intake; adequate hematological, liver
and renal functions; written informed consent.
EXCLUSION CRITERIA
Patients are excluded for any of the following reasons:
apparent infection; serious co-morbidities such as cardiovas-
cular disease, pulmonary ﬁbrosis or intestinal pneumonia,
bleeding tendency, uncontrolled hypertension, poorly con-
trolled diabetes mellitus or another serious medical condi-
tion; a synchronous or metachronous active malignancy;
central nervous system disorder; a previous history of severe
drug-induced allergy; pregnancy or breastfeeding.
TREATMENT METHODS
The experimental treatment consists of two phases: preopera-
tive chemotherapy and surgical resection.
CHEMOTHERAPY
Preoperative chemotherapy consisted of docetaxel 35 mg/m
2
as a 1-h intravenous infusion on Days 1 and 15, cisplatin
35 mg/m
2 as a 2-h intravenous infusion on Days 1 and 15
with hyperhydration and S-1, which is administered orally at
ad o s eo f8 0m g / m
2/day divided into two split daily dose for
14 days followed by 14 days of rest. This regimen performed
two cycles every 4 weeks.
SURGERY
After two cycle of DCS therapy, conventional examinations
(such as a CT scan of the whole abdomen and chest, and en-
doscopy of the upper gastrointestinal tract), were carried out
to assess the resectability of the tumors. Surgery was per-
formed between 4 and 8 weeks after the completion of
chemotherapy. The type of operation depended on the loca-
tion and extent of the primary lesion, but the resection lines
had to be at least 5 cm from the edge of the macroscopic
tumor. En bloc resection of adjacent organs was performed
when their involvement was suspected. D2 lymphadenect-
omy was routinely performed as described earlier and if ne-
cessary, para-aortic lymphadenectomy was also permitted.
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All resected specimens were examined by pathologists and
the pathological response to chemotherapy was evaluated
according to the criteria of the Japanese Research Society
for Gastric Cancer (9). Lesions were graded according to the
amount of viable tumor cells of the tumor as follows:
Grade 0, no evidence of effect; Grade 1a, viable tumor cells
occupy more than two-thirds of the tumorous area; Grade
1b, viable tumor cells remain in more than one-third but less
than two-thirds of the tumorous area; Grade 2, viable tumor
cells remain in less than one-third of the tumorous area;
Grade 3, no viable tumor cells remain. In this study, patients
showing Grades 0 and 1a were regarded as pathological non-
r e s p o n d e r sa n dt h o s es h o w i n gG r a d e s1 b ,2a n d3w e r e
regarded as pathological responders.
FOLLOW-UP
S-1 80 mg/m
2/day as adjuvant chemotherapy is allowed after
R0 resection for 1 year, if possible. For patients with conse-
quent R1–2 resection or non-resection, subsequent therapy
is not stipulated and is decided by each clinician.
STUDY DESIGN AND STATISTICAL METHODS
This trial determined the efﬁcacy and safety of combined
treatment of preoperative chemotherapy followed by surgery
for locally advanced gastric cancer. In JCOG0210 study,
pRR of patients with preoperative chemotherapy consisting
of S-1 and cisplatin followed by gastrectomy was 48%.
Regarding the regimen in this study, triplet regimen is more
powerful than doublet regimen in JCOG0210. Therefore, the
primary hypothesis was that a 70% pRR would be achiev-
able using this regimen but a pRR of ,50% would not be
desirable. In this Phase II trial, the planned sample size was
50 patients, which was calculated by Southwest Oncology
Group’s two-stage attained design based on a target pRR of
70% and a minimum pRR of 50%, with an a error of 0.05
and a,b error of 0.2. Assuming a dropout or ineligibility rate
of 10%, the target number of enrolled patients was deter-
mined to be 55 patients.
UMIN REGISTRATION OF THE PROTOCOL
The study protocol was registered to the UMIN Clinical
Trials Registry (UMIN000001858) on 1 July 2009.
PARTICIPATING INSTITUTIONS
Surgery departments of the following 25 centers from north
to south of Japan were participating in the trial:
Hirosaki University Hospital, Yamagata Prefectural Central
Hospital, Higashiohmiya General Hospital, Tokyo Women’s
Medical University Hospital, Tokyo Metropolitan Cancer
Center Komagome Hospital, IUHW Mita Hospital, Niigata
Cancer Center Hospital, Niigata City General Hospital,
Niigata University Medical and Dental Hospital, Saiseikai
Daini Niigata Hospital, Nagaoka Central General Hospital,
Toyama Prefectural Central Hospital, Kanazawa University
Hospital, Fukui University Hospital, Hiratsuka City Hospital,
Gunma Prefectural Center Hospital, Saitama Medical Center,
Kyoto Prefectural University Hospital, Gifu City Hospital,
Kinki University Hospital, Osaka Medical Center Hospital,
Hiroshima City Hospital, Hiroshima Red Cross Hospital,
Shikoku Cancer Center Hospital, Kagawa University
Hospital, Ehime University Hospital, Nanpu Hospital.
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